Chronic Obstructive Pulmonary Disease (COPD) Market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 10.7 billion in 2018 and is projected to register 4.2% CAGR over the forecast period.
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Its symptoms include breathing difficulty, cough, mucus production and wheezing. People with COPD are at increased risk of developing heart disease, lung cancer, and several other health conditions.
Factors such as the high prevalence of chronic respiratory diseases, technological advancements and new product launches, and increasing demand for home care therapeutic devices are expected to drive the market growth. According to a report published by the World Health Organization in 2017, approximately 65 million people suffered from COPD globally.
However, stringent government regulations are expected to hamper the market growth.
Segmentation
The global chronic obstructive pulmonary disease (COPD) market has been segmented into COPD type, treatment type, end-user, and region.
Based on COPD type, the global chronic obstructive pulmonary disease (COPD) market has been divided into emphysema and chronic bronchitis.
The global chronic obstructive pulmonary disease (COPD) market, by treatment type, has been segmented into drugs, surgery, and oxygen therapy. The drugs segment is further segmented into bronchodilator monotherapy and anti-inflammatory drugs. Bronchodilator monotherapy is further sub-segmented into short-acting beta2-agonists (SABAs), long-acting beta2-agonists (LABAs), and anticholinergic agents. The anti-inflammatory drugs sub-segment is further classified into oral & inhaled corticosteroids and anti-leukotrienes. The surgery segment is sub-segmented into lung volume reduction surgery (LVRS), lung transplant, bullectomy, and others.
The global chronic obstructive pulmonary disease (COPD) market, by end-user, has been segmented into hospitals & clinics, home care settings, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The chronic obstructive pulmonary disease (COPD) market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European chronic obstructive pulmonary disease (COPD) market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe.
The chronic obstructive pulmonary disease (COPD) market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The Middle East & Africa chronic obstructive pulmonary disease (COPD) market is segmented into the Middle East and Africa.
Key Players
Abbott Laboratories (US), Almirall (Spain), Astellas Pharma (Japan), AstraZeneca (UK), Boehringer Ingelheim (Germany), Circassia Pharmaceuticals (UK), GlaxoSmithKline (UK), Novartis AG (Switzerland), Pfizer, Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel) are some of the key players operating in the global chronic obstructive pulmonary disease (COPD) market.
Global Chronic Obstructive Pulmonary Disease (COPD) Market, by COPD Type
- Emphysema
- Chronic Bronchitis
Global Chronic Obstructive Pulmonary Disease (COPD) Market, by Treatment Type
- Drugs
- Bronchodilator Monotherapy
- Short-Acting Beta2-Agonists (SABAs)
- Long-Acting Beta2-Agonists (LABAs)
- Anti-Cholinergic Agents
- Anti-Inflammatory Drugs
- Oral and Inhaled Corticosteroids
- Anti-Leukotrienes
- Surgery
- Lung Volume Reduction Surgery (LVRS)
- Lung Transplant
- Bullectomy
- Others
- Oxygen Therapy
Global Chronic Obstructive Pulmonary Disease (COPD) Market, by End User
- Hospitals and Clinics
- Homecare Settings
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization